UCB and Oxford University announce new R&D partnership
New collaboration to develop research in immunology and neurology
These combined resources and expertise will give the best possible chance of turning innovative research into new medicines for patients, an area identified as a priority in the recent government Strategy for UK Life Sciences.
Professor Sir John Bell (Regius Professor of Medicine at Oxford University and former president of the Academy of Medical Sciences) and David Willetts (Minister for Universities and Science) joined Roch Doliveux (Chief Executive, UCB and Chairman of the Innovative Medicines Initiative) and Ismail Kola (Executive Vice President and President of New Medicines™ UCB) at UCB to sign the agreement.
The Oxford-UCB partnership will be funded by a contribution of £3.6 million from UCB and will run over 3 years. A steering committee of UCB and Oxford University representatives will oversee the collaboration via regular meetings to scope out and monitor new projects. Between five and 10 projects will be selected for investigation over the course of the three-year agreement.
Other news from the department science
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.